Featured

Hamadeh Questions Potential FDA Restrictions for Popular Thyroid Medications

Representative Abe Hamadeh (R-AZ) is writing to Food and Drug Administration (FDA) Commissioner Dr. Martin Makary over potential restrictions to popular thyroid medications.

For additional context, the FDA announced earlier in August that they would potentially "take action against marketed unapproved animal-derived thyroid (ADT) products (sometimes described as desiccated thyroid extract [DTE] products)," as Medscape described.

The action was noted as not taking place immediately, as the FDA intends to allow patients using these animal-derived thyroid medications to transition to approved, albeit synthetic, products, as no ADT currently has FDA approval, despite intentions to approve one. However, this sparked backlash on social media.

In his letter, Rep. Hamadeh said, "Many of these patients have found desiccated thyroid medications to be more effective than synthetic alternatives for managing their thyroid conditions," adding, "Any disruption to their treatment regimens could have serious health consequences and undermine the doctor-patient relationship."

As a result, he demanded answers to several questions by September 5th, asking what action the FDA plans to take against these ADT products, the justification for those restrictions, any consideration of potential fallout, and how the FDA will continue to ensure that patients receive effective thyroid medication.

"I have heard from veterans, mothers, and other individuals in my district, who believe their health will be negatively affected by the elimination of these medications," Rep. Hamadeh continued. "They have all shared their positive experiences with these drugs and their belief that their quality of life could be negatively impacted without them. This is of deep concern to me."

The Arizona Congressman further stated he has "confidence that Dr. Makary and his team will give serious consideration to the concerns of these patients, and I look forward to providing his team's answers to my constituents."

"The FDA's primary mission should be ensuring drug safety and efficacy, not unnecessarily restricting access to medications with established track records of safety and effectiveness, and I believe the Trump administration is committed to that mission," Hamadeh concluded.

On Friday, Senator Ruben Gallego (D-AZ) similarly wrote to the Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz, urging safeguards to prevent Medicare Part D prescription premium hikes.

Grayson Bakich

Florida born and raised, Grayson Bakich is a recent recipient of a Master’s Degree in Political Science at the University of Central Florida. His thesis examined recent trends in political polarization and how this leads into justification of violence.

Recent Posts

President Trump Will Make NASA Great Again, Again

By Jeff DeWit As a proud American and loyal longtime supporter of President Donald J.…

4 hours ago

Steve Montenegro Steps In to Defend Arizona Birth Certificate Law

House Speaker Steve Montenegro is taking matters into his own hands after Attorney General Kris…

12 hours ago

Military Build Up: Is Trump Inching Closer to Dropping Bombs on Maduro?

As deadly military strikes continue against Venezuela-based and supported drug cartels in the Caribbean, it…

12 hours ago

Will ASU President Michael Crow Follow UA Lead? ASU Faces Federal Compact Decision

Arizona State University President Michael Crow faces the decision of whether to accept the Trump…

13 hours ago

Kris Mayes Officially Sues Mike Johnson over Grijalva’s Delay

Attorney General Kris Mayes is taking House Speaker Mike Johnson to federal court, claiming he's…

13 hours ago

Ruben Gallego Says Shutdown 'Does Suck,' Emphasizes Healthcare Negotiations

During an appearance on Fox Business' Claman Countdown, Senator Ruben Gallego (D-AZ) discussed the ongoing…

14 hours ago